Keywords
Eczema
Dermatitis eczematous
Immunologic factors
Drug therapy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the efficacy and safety of immunomodulators in the treatment of atopic dermatitis, analyzing the evidence available in the literature. Methods: A literature review was performed based on the selection of relevant scientific studies, considering scientific clinical trials. The search was conducted in five national and international scientific databases, using specific descriptors related to the topic. Results: The results indicate that immunomodulators have benefits in controlling inflammation and reducing the severity of symptoms, but there are variations in the clinical response among patients. In addition, the methodological specifications of the studies studied make it difficult to make a definitive decision on the superiority of this approach in relation to other available options. Therefore, there is a need for more robust and longer-lasting clinical trials to assess long-term safety. The heterogeneity of protocols and the lack of standardization in the inclusion and exclusion criteria of patients are challenges for the consolidation of immunomodulators as the treatment of choice. Conclusion: Immunomodulators represent a relevant therapeutic alternative for severe atopic dermatitis, but their clinical application still requires greater scientific support. Future studies should focus on methodological standardization and prolonged patient monitoring to ensure greater safety and efficacy in the use of these medications.
References
ALBRES DE ABREU M, FIGUEIREDO BRANDÃO BJ. Imunobiológico em crianças com dermatite atópica. BWS Journal, 2021; 4: 4.
ANTUNES AA, et al. Guia prático de atualização em dermatite atópica-Parte I: etiopatogenia, clínica e diagnóstico. Posicionamento conjunto da Associação Brasileira de Alergia e Imunologia e da Sociedade Brasileira de Pediatria. Arq. Asma, Alerg. Imunol, 2017.
ARAÚJO WCO. Recuperação da informação em saúde: construção, modelos e estratégias. Conv. Ciênc. Inform., 2020; 3(2)
BECK LA, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. Journal of the American Academy of Dermatology, 2023; 88(4).
BELDA W, et al. Tratado de Dermatologia. 2 ed. São Paulo: Atheneu, 2014.
BIEBER T, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. Journal of the European Academy of Dermatology and Venereology, 2022; 36(9).
BRAGA SG, et al. Dermatite atópica: uma revisão dos seus impactos na qualidade de vida de pacientes pediátricos. Brazilian Journal of Health Review, 2023; 6(1).
CHAN S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA pediatrics,2020; 174(1).
DE BRUIN-WELLER M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). British Journal of Dermatology, 2018; 178.
DONATO H, DONATO M. Etapas na condução de uma revisão sistemática. Acta medica portuguesa, 2019; 32(3).
DOS REIS AP, AARESTRUP F M. Imunoterapia e imunobiológicos na dermatite atópica. Arquivos de Asma, Alergia e Imunologia, 2019; 3(2).
GUILLEN JSQ, et al. Abordagens no tratamento da dermatite atópica. BWS Journal, 2021; 4.
HADI HA, et al. The epidemiology and global burden of atopic dermatitis: a narrative review. Life, 2021; 11(9).
IYENGAR SR, et al. Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial. International Archives of Allergy and Immunology, 2013; 162(1).
JADAD AR, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials, 1996; 17(1).
KIM J, et al. Pathophysiology of atopic dermatitis: Clinical implications. In: Allergy and asthma proceedings. OceanSide Publications, 2019.
MARTÍNEZ MFA, et al. Omalizumab for the treatment of atopic dermatitis. Actas Dermo-Sifiliográficas, 2012; 03(7).
OLDHOFF JM, et al. Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy, 2005; 60(5).
POLMANN H, et al. Análise da qualidade metodológica de ensaios clínicos randomizados (ECR) com as ferramentas Escala Jadad e Escala PEDro. In: CANTO, Graziela de Luca; STEFANI, Cristine Miron; MASSIGNAN, Carla (org.). Risco de viés em revisões sistemáticas: guia prático. Florianópolis: Centro Brasileiro de Pesquisas Baseadas em Evidências – COBE UFSC, 2021. Cap. 6.
PRADO E, et al. Dermatite atópica grave: guia prático de tratamento da Associação Brasileira de Alergia e Imunologia e Sociedade Brasileira de Pediatria. Arq. Asma, Alerg. Imunol, 2022.
PRISMA. 2021.Transparent Reporting of System Review and Meta-Analyses [internet]. Disponível em: https://www.prisma-statement.org. Acessado em: 17 de fevereiro de 2025.
ROBINET E, et al. CD4 monoclonal antibody administration in atopic dermatitis. Journal of the American Academy of Dermatology, 1997; 36(4).
RUZICKA T, et al. Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis. The New England Journal of Medicine, 2017; 376.
SANTOS P, et al. Qualidade de vida em crianças e adolescentes com dermatite atópica e seus cuidadores. Rev Port Imunoalergologia, 2021; 29(1).
SARINHO FW, et al. Guia prático para o uso de imunobiológicos em doenças alérgicas- ASBAI.Arq Asma Alerg Imunol, 2023; 7(4).
SILVERBERG JI, et al. Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis. The Journal of Allergy and Clinical Immunology: In Practice, 2022; 10(5).
SIMPSON EL, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). Journal of the American Academy of Dermatology, 2018; 78(5).